AU2019255755B2 - STAT3 inhibitors - Google Patents

STAT3 inhibitors Download PDF

Info

Publication number
AU2019255755B2
AU2019255755B2 AU2019255755A AU2019255755A AU2019255755B2 AU 2019255755 B2 AU2019255755 B2 AU 2019255755B2 AU 2019255755 A AU2019255755 A AU 2019255755A AU 2019255755 A AU2019255755 A AU 2019255755A AU 2019255755 B2 AU2019255755 B2 AU 2019255755B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
cancer
ora
cycloalkyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019255755A
Other languages
English (en)
Other versions
AU2019255755A1 (en
Inventor
William E. Bauta
William R. Cantrell Jr.
David John Tweardy
Sofia De Achaval Wied
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Tvardi Therapeutics Inc
Original Assignee
Baylor College of Medicine
Tvardi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine, Tvardi Therapeutics Inc filed Critical Baylor College of Medicine
Publication of AU2019255755A1 publication Critical patent/AU2019255755A1/en
Application granted granted Critical
Publication of AU2019255755B2 publication Critical patent/AU2019255755B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polymerisation Methods In General (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2019255755A 2018-04-19 2019-04-18 STAT3 inhibitors Active AU2019255755B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862659872P 2018-04-19 2018-04-19
US62/659,872 2018-04-19
US201962793491P 2019-01-17 2019-01-17
US62/793,491 2019-01-17
PCT/US2019/028135 WO2019204614A1 (en) 2018-04-19 2019-04-18 Stat3 inhibitors

Publications (2)

Publication Number Publication Date
AU2019255755A1 AU2019255755A1 (en) 2020-12-03
AU2019255755B2 true AU2019255755B2 (en) 2024-07-25

Family

ID=68240338

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019255755A Active AU2019255755B2 (en) 2018-04-19 2019-04-18 STAT3 inhibitors

Country Status (18)

Country Link
US (2) US11826315B2 (https=)
EP (2) EP3773537B1 (https=)
JP (1) JP7411315B2 (https=)
KR (1) KR102792113B1 (https=)
CN (1) CN112367984B (https=)
AU (1) AU2019255755B2 (https=)
BR (1) BR112020021329A2 (https=)
DK (1) DK3773537T3 (https=)
ES (1) ES2911428T3 (https=)
HU (1) HUE059318T2 (https=)
IL (1) IL278112B2 (https=)
MX (1) MX2020011065A (https=)
MY (1) MY207195A (https=)
PH (1) PH12020551728A1 (https=)
PL (1) PL3773537T3 (https=)
PT (1) PT3773537T (https=)
SG (1) SG11202010347XA (https=)
WO (1) WO2019204614A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7411315B2 (ja) * 2018-04-19 2024-01-11 トゥヴァルディ セラピューティクス，インク． Ｓｔａｔ３阻害剤
CN114761405A (zh) * 2019-11-29 2022-07-15 南京明德新药研发有限公司 抗hbv的1,7-萘啶类化合物
JP2023504194A (ja) * 2019-12-03 2023-02-01 ベイラー カレッジ オブ メディスン インスリン耐性における使用方法のための治療化合物
JP2023520273A (ja) * 2020-01-24 2023-05-17 トゥヴァルディ セラピューティクス，インク． 治療化合物、製剤、およびその使用
CN114286684B (zh) * 2020-07-27 2024-01-05 华中科技大学 与stat3相关的疾病的预防和/或治疗
AR128676A1 (es) * 2022-03-01 2024-06-05 Tvardi Therapeutics Inc Compuestos terapéuticos, formulaciones, uso y método de preparación
US20250170079A1 (en) * 2022-03-04 2025-05-29 Tvardi Therapeutics, Inc. Combinations of stat-inhibitors and immune checkpoint inhibitors for the treatment and/or management of cancer
CA3254067A1 (en) 2022-06-15 2023-12-21 Tvardi Therapeutics, Inc. STAT3 INHIBITOR MEDICINES
TW202412749A (zh) * 2022-07-21 2024-04-01 美商特梵迪治療股份有限公司 治療性化合物、調配物、及其用途
EP4633620A1 (en) * 2022-12-12 2025-10-22 Tvardi Therapeutics, Inc. Stat3 inhibitors for use in the treatment of non-viral liver cancer
WO2025184497A1 (en) * 2024-02-29 2025-09-04 Tvardi Therapeutics, Inc. Stat3 inhibitors for use in the treatment of cancer

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4279909A (en) 1980-02-13 1981-07-21 Fujisawa Pharmaceutical Co., Ltd. Antiallergic method
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6492428B1 (en) 2000-07-26 2002-12-10 The Picower Institute For Medical Research Compounds having MIF antagonist activity
US6197749B1 (en) 1997-10-29 2001-03-06 Ajinomoto Co., Inc. Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes
CA2413878A1 (en) 2000-06-20 2001-12-27 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
JP2005522457A (ja) 2002-02-26 2005-07-28 ノース ショア−ロング アイランド ジューイッシュ リサーチ インスティチュート 脳ムスカリン性レセプターの刺激による炎症性サイトカイン産生の阻害
WO2005026134A1 (en) 2003-09-17 2005-03-24 Novartis Ag Organic compounds
US20050287664A1 (en) 2004-05-27 2005-12-29 Ming-Ji Fann Cellular proliferation control factors
US20060148715A1 (en) 2004-12-20 2006-07-06 Baylor College Of Medicine Structural requirements for STAT3 binding and recruitment to phosphotyrosine ligands
US20100035793A1 (en) 2005-07-27 2010-02-11 Cheh Peng Lim Modulators
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
CA2636909A1 (en) 2006-01-13 2007-07-26 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production with tanshinones
WO2007136858A2 (en) 2006-05-19 2007-11-29 H. Lee Moffitt Cancer Center & Research Institute Small molecule inhibitors of stat3 with anti-tumor activity
US20090264353A1 (en) 2007-10-19 2009-10-22 Santaris Pharma A/S Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
HRP20160625T1 (hr) * 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
WO2009038784A1 (en) 2007-09-21 2009-03-26 Amgen Inc. Triazole fused heteroaryl compounds as p38 kinase inhibitors
EP2299999B1 (en) * 2008-06-04 2017-08-16 Baylor College Of Medicine Stat3 inhibitors
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor
WO2010080581A2 (en) 2008-12-19 2010-07-15 The Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Valproic acid, derivatives, analogues, and compositions including same and methods for their therapeutic use
US8557805B2 (en) 2008-12-29 2013-10-15 Takeda Pharmaceutical Company Limited Fused ring compound and use thereof
US9891213B2 (en) 2009-01-12 2018-02-13 The Board Of Trustees Of The Leland Stanford Junior University Granulocyte-based methods for detecting and monitoring immune system disorders
CA2781706A1 (en) * 2009-11-24 2011-06-03 The Ohio State University Transcription factor inhibitors and related compositions, formulations and methods
FR2962649B1 (fr) 2010-07-19 2025-10-24 Conservatoire Nat Arts Et Metiers Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
US20140371188A1 (en) 2011-11-23 2014-12-18 University Of Iowa Research Foundation Compositions and methods for inhibiting muscle atrophy and inducing muscle hypertrophy
EP2708535A1 (en) 2012-05-11 2014-03-19 Les Laboratoires Servier Agents for treating disorders involving modulation of ryanodine receptors
CN102766103B (zh) * 2012-07-24 2014-12-10 齐鲁制药有限公司 2-硫代-4-胺基-1-萘酚衍生物、其制备方法和用途
AU2014290363B2 (en) * 2013-07-18 2019-02-21 Baylor College Of Medicine Methods and compositions for treatment of fibrosis
AU2014290368B2 (en) 2013-07-18 2019-07-11 Baylor College Of Medicine Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
US20150031714A1 (en) 2013-07-18 2015-01-29 Baylor College Of Medicine Methods and compositions for prevention of allergic reaction
WO2017083719A1 (en) * 2015-11-13 2017-05-18 William Marsh Rice University Transition metal free methods of synthesis of biaryl compounds
JP7411315B2 (ja) * 2018-04-19 2024-01-11 トゥヴァルディ セラピューティクス，インク． Ｓｔａｔ３阻害剤
US11026905B2 (en) * 2018-04-19 2021-06-08 Tvardi Therapeutics, Inc. STAT3 inhibitors
JP2023520273A (ja) * 2020-01-24 2023-05-17 トゥヴァルディ セラピューティクス，インク． 治療化合物、製剤、およびその使用

Also Published As

Publication number Publication date
CN112367984A (zh) 2021-02-12
ES2911428T3 (es) 2022-05-19
MY207195A (en) 2025-02-05
KR102792113B1 (ko) 2025-04-04
KR20210011925A (ko) 2021-02-02
JP7411315B2 (ja) 2024-01-11
US20240058284A1 (en) 2024-02-22
US11826315B2 (en) 2023-11-28
AU2019255755A1 (en) 2020-12-03
BR112020021329A2 (pt) 2021-04-27
IL278112B2 (en) 2023-07-01
JP2021521243A (ja) 2021-08-26
EP3773537A1 (en) 2021-02-17
US20210114980A1 (en) 2021-04-22
IL278112B1 (en) 2023-03-01
PL3773537T3 (pl) 2022-05-23
PT3773537T (pt) 2022-04-19
MX2020011065A (es) 2021-01-20
EP4070790A1 (en) 2022-10-12
SG11202010347XA (en) 2020-11-27
HUE059318T2 (hu) 2022-11-28
CA3097403A1 (en) 2019-10-24
PH12020551728A1 (en) 2021-06-14
IL278112A (https=) 2020-12-31
EP3773537B1 (en) 2022-03-23
CN112367984B (zh) 2024-05-10
EP3773537A4 (en) 2021-05-26
DK3773537T3 (en) 2022-04-25
WO2019204614A1 (en) 2019-10-24

Similar Documents

Publication Publication Date Title
AU2019255755B2 (en) STAT3 inhibitors
US11026905B2 (en) STAT3 inhibitors
CA3133753A1 (en) Novel small molecule inhibitors of tead transcription factors
US8993562B2 (en) Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions
US20200308165A1 (en) Compounds as Ras Inhibitors and Use Thereof
CA3149374A1 (en) Degraders of cyclin-dependent kinase 7 (cdk7) and uses thereof
BR112015017963B1 (pt) Composto de fenil amino pirimidina deuterado, método para preparar a composição farmacêutica, composição farmacêutica e uso do composto
US20210235688A1 (en) Methods for measuring and stabilizing stat3 inhibitors
MX2014012992A (es) Derivado de quinazolindiona.
EP4041408A1 (en) Aryl heterobicyclic compounds as kv1.3 potassium shaker channel blockers
WO2022005961A1 (en) Prpk inhibitors
CA3097403C (en) Stat3 inhibitors
HK40073672A (en) Stat3 inhibitors
JP7815213B2 (ja) ベンジルアミン誘導体、その調製方法およびその用途
HK40038526A (en) Stat3 inhibitors
HK40038526B (en) Stat3 inhibitors
EP4519250A1 (en) Pyridone compounds as trpa1 inhibitors
EA043779B1 (ru) Ингибиторы stat3
US7943611B2 (en) Imidazo[1,2-A]pyridin-3-yl-acetic acid hydrazides, processes, for their preparation and pharmaceutical uses thereof
WO2019120198A1 (zh) 一类喹啉衍生物
WO2025014922A1 (en) Bicyclic and monocyclic trpa1 inhibitors
EP4658262A1 (en) Bicyclic imide compounds as trpa1 inhibitors
WO2020167567A1 (en) Heterocyclic compounds and their use in the treatment of amyloid-related diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)